癌症疫苗OSE2101对比化疗在免疫治疗耐药的HLA-A2阳性晚期非小细胞肺癌患者中的随机开放对照研究:ATALANTE-1
ATALANTE-1是一项两步开放标签研究,将219例HLA-A2阳性晚期非小细胞肺癌且对免疫检查点抑制剂耐药的患者按2:1随机分配至OSE2101或标准化疗。总体中位OS无显著差异(HR 0.86,P=0.36);在继发性耐药亚组中,OSE2101较化疗显著改善中位OS(11.1 vs 7.5个月,HR 0.59,P=0.017),且≥3级不良事件发生率更低(11.4% vs 35.1%,P=0.002)。
要点
- 总体人群中OSE2101较化疗的中位OS无显著差异(HR 0.86,P=0.36)。
- 继发性耐药亚组中OSE2101较化疗显著改善中位OS(11.1 vs 7.5个月,HR 0.59,P=0.017)。
- OSE2101组≥3级不良事件发生率低于化疗组(11.4% vs 35.1%,P=0.002)。
核心结论
- 在HLA-A2阳性晚期非小细胞肺癌且对免疫治疗继发性耐药的患者中,OSE2101较化疗延长生存且安全性更好。
- 作者认为需在该人群中进一步评估OSE2101。
研究设计与样本
- ATALANTE-1为两步开放标签研究,评估OSE2101对比标准化疗的疗效与安全性。
- 纳入HLA-A2阳性晚期非小细胞肺癌、无可用靶向改变、经序贯或同步化疗和免疫检查点抑制剂治疗失败的患者。
- 共219例患者按2:1随机分配至OSE2101组(139例)或标准化疗组(80例)。
- 标准化疗为多西他赛或培美曲塞。
- 主要终点为总生存期;计划按Fleming设计进行期中OS无效性分析。
主要发现
- 总体人群中,OSE2101组较标准化疗组的中位OS无显著优势(HR 0.86,95%CI 0.62-1.19,P=0.36)。
- 继发性耐药亚组中,OSE2101组较标准化疗组显著改善中位OS(11.1 vs 7.5个月;HR 0.59,95%CI 0.38-0.91,P=0.017)。
- 继发性耐药亚组中,OSE2101组较标准化疗组显著改善进展后生存(HR 0.46,P=0.004)。
- 继发性耐药亚组中,OSE2101组较标准化疗组显著延长ECOG体能状态恶化时间(HR 0.43,P=0.006)。
- 继发性耐药亚组中,OSE2101组较标准化疗组显著改善QLQ-C30总体健康状况(P=0.045)。
关键数值与推荐
- 继发性耐药定义为二线免疫检查点抑制剂单药治疗后≥12周失败。
- 总体人群OS:OSE2101组 vs 标准化疗组 HR 0.86(95%CI 0.62-1.19),P=0.36。
- 继发性耐药亚组中位OS:OSE2101组11.1个月 vs 标准化疗组7.5个月,HR 0.59(95%CI 0.38-0.91),P=0.017。
- 继发性耐药亚组进展后生存:HR 0.46,P=0.004;ECOG体能状态恶化时间:HR 0.43,P=0.006。
- ≥3级不良事件:OSE2101组11.4% vs 标准化疗组35.1%,P=0.002。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因COVID-19决定提前停止入组。
- 作者认为需在该人群中进一步评估OSE2101。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with advanced non-small-cell lung cancer (NSCLC) treated with immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary resistance) or after durable benefit (secondary resistance). The cancer vaccine OSE2101 may invigorate antitumor-specific immune responses after ICB failure. The objective of ATALANTE-1 was to evaluate its efficacy and safety in these patients. PATIENTS AND METHODS: ATALANTE-1 was a two-step open-label study to evaluate the efficacy and safety of OSE2101 compared to standard-of-care (SoC) chemotherapy (CT). Patients with human leukocyte antigen (HLA)-A2-positive advanced NSCLC without actionable alterations, failing sequential or concurrent CT and ICB were randomized (2 : 1) to OSE2101 or SoC (docetaxel or pemetrexed). Primary endpoint was overall survival (OS). Interim OS futility analysis was planned as per Fleming design. In April 2020 at the time of interim analysis, a decision was taken to prematurely stop the accrual due to coronavirus disease 2019 (COVID-19). Final analysis was carried out in all patients and in the subgroup of patients with ICB secondary resistance defined as failure after ICB monotherapy second line ≥12 weeks. RESULTS: Two hundred and nineteen patients were randomized (139 OSE2101, 80 SoC); 118 had secondary resistance to sequential ICB. Overall, median OS non-significantly favored OSE2101 over SoC {hazard ratio (HR) [95% confidence interval (CI)] 0.86 [0.62-1.19], P = 0.36}. In the secondary resistance subgroup, OSE2101 significantly improved median OS versus SoC [11.1 versus 7.5 months; HR (95% CI) 0.59 (0.38-0.91), P = 0.017], and significantly improved post-progression survival (HR 0.46, P = 0.004), time to Eastern Cooperative Oncology Group (ECOG) performance status deterioration (HR 0.43, P = 0.006) and Quality of Life Questionnaire Core 30 (QLQ-C30) global health status compared to SoC (P = 0.045). Six-month disease control rates and progression-free survival were similar between groups. Grade ≥3 adverse effects occurred in 11.4% of patients with OSE2101 and 35.1% in SoC (P = 0.002). CONCLUSIONS: In HLA-A2-positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to CT. Further evaluation in this population is warranted.
引用
- Besse B, Felip E, Garcia Campelo R, et al. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann Oncol. 2023. PMID: 37704166. doi:10.1016/j.annonc.2023.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。